King Pharmaceuticals Loses Rehearing Bid

Law360, New York (December 3, 2007, 12:00 AM EST) -- King Pharmaceuticals, Inc. revealed Monday that a federal appeals court has nixed its bid for a rehearing in a patent dispute over its top-selling hypertension medicine.

The U.S. Court of Appeals for the Federal Circuit denied the pharmaceutical firm's September petition for rehearing and rehearing en banc in a suit over the validity of a patent for ramipril, which King Pharmaceuticals sells under the brand name Altace, the drug maker said Monday.

“King is evaluating its remaining legal options with respect to the patent following today's...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.